AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03927976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Path2Quit - culturally specific text message intervention
Description: SMS text delivers over 6 weeks with links to 20-120 second video clips from PTF. The message library contains 155 videos and assessment questions. First message is tailored to wake-up times, and the topic of the video (e.g., Never Quit Quitting) accompanies the text. Messages are pushed to participants 1-2 times/day, with 24/7 access to messages pulled from 3 keywords (HELP1, JONES, SLIP). Participants also receive inquiry texts, designed to push videos of interest/relevance to the individual. The cultural adaptations are infused throughout the video segments. Topics include deep structure: race and smoking in general, African American smoking statistics; norms for smoking; concerns about nicotine replacement/medication; family/collectivism; unique stressors; racism/discrimination, depression; co-morbid addiction; neighborhood/environmental influences; menthol cigarettes; race-specific weight issues and concerns; and working as a community against the tobacco industry.
Study NCT05126615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Auriculotherapy
Description: Application of a bolus of 5 μ of liquid nitrogen via a cryospray on the auriculotherapy points A4, C18, D9, C9, DIX, H13, G14 and FXVII, chosen according to a neurophysiological reasoning taking into account the surgical intervention performed and innervation of the anatomical region affected by the intervention.
Study NCT05126615 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Chronic Post-Surgical Pain evaluation
Description: Different questionnaires :~BPI : Brief Pain Inventory DN4
Study NCT05126615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic Post-Surgical Pain evaluation
Description: Different questionnaires :~BPI : Brief Pain Inventory DN4
Study NCT03852212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manipulation
Description: Thrust technique application
Study NCT00693719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 50 mg PO x14 days followed by 2 weeks off, 28 day/Cycle
Study NCT00693719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan hydrochloride
Description: Irinotecan 100 mg/m2 IV days 1 and 15, 28 day/Cycle
Study NCT05066893 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telehealth visits
Description: intensive visits with doctor
Study NCT05066893 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: telehealth visits
Description: intensive visits with doctor
Study NCT00928980 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy
Description: Mindfulness Based Cognitive Therapy is an 8-week during group intervention encompassing meditation practice and cognitive therapy techniques.
Study NCT00928980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimal Medical Care
Description: Therapeutic dose of antidepressant medication
Study NCT00928980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Care
Description: Therapeutic dose of antidepressant medication
Study NCT01232946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 1.8mg subcutaneous qd for 3 months
Study NCT01232946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: 5units subcutaneous bid titrated to fasting glucose of \<130mg/dL for 3 months
Study NCT01232946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide plus insulin detemir
Description: liraglutide 1.8mg subq qd plus insulin detemir 5units bid titrated to fasting blood glucose \<130mg/dL for 3 months.
Study NCT00734929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant + Dexamethasone
Description: Aprepitant 40 mg + Dexamethasone 10 mg
Study NCT00734929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron + Dexamethasone
Description: Ondansetron 4 mg + Dexamethasone 10 mg
Study NCT03550339 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SURG
Description: bariatric surgery according to Finnish Current Care Guidelines for Obesity in adults
Study NCT03550339 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DIET
Description: dietary weight loss program according to Finnish Current Care Guidelines for Obesity in adults
Study NCT03550339 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HAES
Description: treatment is based on the previously published procedure (e.g. Bacon et al. 2002) and Health At Every Size trademark, consisting of body acceptance, eating behaviour, physical activity, nutrition, and social support
Study NCT04729127 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Project ImPACT
Description: Project ImPACT (Improving Parents As Communication Teachers) is an evidence-based parent-mediated intervention program based on best practices in early intervention. The program is designed for young children up to age six with social communication delays, including autism spectrum disorder. Project ImPACT focuses on social engagement, language, social imitation, and play. Project ImPACT is a naturalistic developmental behavioral intervention (NDBI).
Study NCT01904461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vacuum device
Study NCT01904461 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional surgery
Study NCT03866772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol Oral Tablet
Description: 50 mcg oral consumption
Study NCT03866772 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: double balloon device for cervical ripening
Description: insertion for 6 hours and followed by the above mentioned protocol
Study NCT04873778 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Kinesio taping
Description: Kinesio taping: Invented by Japan Dr.Kase, increase circulation by creating lifts skin,release pain and inflammation, stabilize joints
Study NCT04873778 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: Kinesio taping: Invented by Japan Dr.Kase, increase circulation by creating lifts skin,release pain and inflammation, stabilize joints
Study NCT04873778 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic taping
Description: Dynamic taping: Invented by Kendrick,elasticised with multi-directional rebound and with strong elastic resistance and recoil than KT
Study NCT00003501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Refractory or Recurrent High-Grade Stage II - IV Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study NCT00098293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc + Zidovudine/Lamivudine
Description: maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)
Study NCT03115697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: Rifaximin 550 BD
Study NCT03115697 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Description: Plasmapheresis 8 hrly duration
Study NCT03884894 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: molecular assay
Description: performed with blood culture simultaneously
Study NCT03884894 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood culture
Description: performed with molecular assay simultaneously
Study NCT02465125 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: red blood cell transfusion
Study NCT02442687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JKB-121: 5 mg twice daily
Study NCT02442687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JKB-121: 10 mg twice daily
Study NCT02442687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00849797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Description: 600 mg Tablet
Study NCT00849797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trileptal®
Description: 600 mg Tablet
Study NCT04366544 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Part A1: Survey
Description: Online
Study NCT04366544 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Part A2: Sample collection
Description: Blood and Stool
Study NCT00098293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz + Zidovudine/Lamivudine
Description: efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily)
Study NCT00098293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (UK-427,857) + Zidovudine/Lamivudine
Description: maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)
Study NCT02742974 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FloTrac™ and EV1000™
Description: Interventions to improve cardiovascular performance will be made in all patients whose cardiovascular function is sub-optimal in accordance with routine clinical management during trauma resuscitation. Patients who meet inclusion criteria will be assigned to the intervention or control arm of the study based on the process outlined in the protocol. Patients assigned to the intervention arm will have intra-operative hemodynamic monitoring performed by the anesthesia staff and cardiovascular interventions will be based off of the algorithm described in the protocol. Members of anesthesia or the surgical team can initiate interventions as indicated during routine ICU care or intra-operatively.
Study NCT03666793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: global care
Description: Medication Reconciliation at admission, Multidisciplinary medication review, Medication Reconciliation at discharge
Study NCT03435315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill Exercise- behavioral approach
Description: 12-session, 6-week treadmill exercise program utilizing behavioral techniques while walking
Study NCT03435315 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill Exercise- traditional approach
Description: 12-session, 6-week traditional treadmill exercise program
Study NCT04168138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: D: Decitabine(15mg/m2) d1-5 G: G-CSF（300ug/d） d0-9(stop using when White Blood Cell (WBC)>20\*109/L) T: rhTPO(15000U/d) d3,5,7,9, d11- (Platelet>50\*109/L) A: Aclarubicin(10mg/d) d3-6 C: Cytarabine(15mg Q12h) d3-9
Study NCT00689052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramipexole ER
Study NCT00689052 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03480516 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SDF
Description: 38% silver diamine fluoride solution
Study NCT03480516 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluoride varnish
Description: 5% sodium fluoride varnish
Study NCT03511066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-P27 90 mg/kg
Description: Influenza A treatment drug.
Study NCT03511066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-P27 45 mg/kg
Description: Influenza A treatment drug.
Study NCT03511066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo.
Study NCT05136521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone HCl - new polymer
Description: A single 300 mg dose of the test (T) and of the reference (R) products will be administered to the study subjects in two consecutive periods, according to a randomised 2-sequence cross-over design. A wash-out interval of at least 10 days will elapse between the two administrations. The two investigational products will be administered with 240 mL of still mineral water on day 1 of the two study periods, at 08:00±1 h after an overnight fasting.
Study NCT05136521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone HCl - Contramid®
Description: A single 300 mg dose of the test (T) and of the reference (R) products will be administered to the study subjects in two consecutive periods, according to a randomised 2-sequence cross-over design. A wash-out interval of at least 10 days will elapse between the two administrations. The two investigational products will be administered with 240 mL of still mineral water on day 1 of the two study periods, at 08:00±1 h after an overnight fasting.
Study NCT03077308 — intervention group
Intervention type: PROCEDURE
Intervention: Auditory and Visual Event-related Potentials and EEG
Description: Specifically, through up to three standardized sessions (i.e., annual \[every 10-14 months\]), we will assess AEP and VEP. ERP recordings will also provide data for specific rhythms/band (gamma and alpha) pattern analyses as secondary measures as well as technical control data, which will help to exclude those with co-current seizures.
Study NCT02105857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: grade A+ knee mobilization
Description: grade A+ knee mobilization using the joint active systems knee device, 20minutes twice a day in knee extension and knee flexion
Study NCT00709345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral sessions
Description: Participants will receive 26 weekly 1-hour small-group sessions and 26 weekly 30-minute individual sessions with a study facilitator. After completing treatment, participants will also receive 6 monthly 1-hour booster sessions. All sessions will focus on promoting healthy behaviors, dieting, and exercise.
Study NCT00709345 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Time-matched attention control sessions
Description: Participants will receive 26 weekly 1-hour small-group sessions and 26 weekly 30-minute individual sessions with a study facilitator. After completing treatment, participants will also receive 6 monthly 1-hour booster sessions. All sessions will focus on improving communications, developing healthy techniques for coping with stress, and resolving conflicts.
Study NCT00137280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Chronic Illness Care Model
Description: A care model that integrates greater availability of clinical information, reorganizes the practice system and provider roles, fosters care coordination, and focuses on evidence-based protocols--specifically supported employment and wellness services for individuals with schizophrenia.
Study NCT04253678 — intervention group
Intervention type: DRUG
Intervention: Vortioxetine
Description: Flexible dosing from 5mg to 20mg based on attending psychiatrist's discretion
Study NCT02178189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Calorie Infant formula
Description: Infants were randomized to be fed high calorie formula from 72 hours of life until age 21 days.
Study NCT02178189 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Calorie Infant Formula
Description: Infants were randomized to be fed standard calorie formula from 72 hours of life until age 21 days.
Study NCT01057940 — intervention group
Intervention type: PROCEDURE
Intervention: DBE PEJ placement
Description: One time procedure with follow-up telephone call.
Study NCT01823887 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation (VNS)
Description: Electrical Stimulation of the Vagus Nerve
Study NCT01512173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propranolol gel
Description: Topical administration twice daily
Study NCT01512173 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical administration twice daily
Study NCT02622594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminolevulinic Acid (ALA)
Study NCT02622594 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Environ Cosmetic Roller
Study NCT02622594 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BLU-U IIlluminator
Study NCT01204372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine - Trastuzumab - Erlotinib
Description: Treatment will be administered until disease progression, patient's refusal, unacceptable toxicity or investigator's decision.~* Gemcitabine: IV 1000 mg/m2 on D1, D8, D15, D22, D29, D36 and D43 followed by one week of rest. Subsequently on D1, D8 and D15 followed by one week of rest.~* Trastuzumab: IV once a week; 4 mg/kg over 90 min. at D1, and 2 mg/kg over 30 min. for the subsequent infusions.~* Erlotinib: oral route 100 mg/day from C1D1.
Study NCT05362136 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: perforation of the sinus floor
Description: perforation of the cortical layer of the sinus floor prior to inserting the augmentation material during sinus floor elevation
Study NCT05362136 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no perforation of the sinus floor
Description: standard procedure for sinus floor elevation
Study NCT01312077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: peri- and intraarticular surgical site infiltration before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight with epinephrine made up to a volume of 1.5ml/kg with saline. A catheter will be placed by the surgeon before closure under the sterile surgical conditions and this will be left in situ in the wound. An elastomeric pump will deliver a continuous infusion of levobupivacaine 0.25% at 4ml/hr commencing 6 hours postoperatively and continuing for 24 hours.
Study NCT01312077 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intrathecal morphine
Description: intrathecal morphine bolus 200 micrograms
Study NCT03531567 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Mystic Isle Game
Description: 8 week virtual reality based exercise program
Study NCT03531567 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Home Exercise Program
Description: 8 week standard occupational therapy home exercise program
Study NCT03300453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAAV2/5-hNAGLU
Description: one-time brain intraparenchymal gene therapy dose
Study NCT01596205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robot assisted cognitive training
Description: We developed total 17 software programs for cognitive training with robot which were intended to develop for improvement of following cognitive function;5 programs for memory, 2 for language , 1 for reasoning, 3 for working memory or speed of processing, 2 for calculation and 4 for visuospatial function.
Study NCT01596205 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cognitive training group
Description: Experienced behavioral therapists who had been clinical neuropsychologists for 2 years instructed the participants in cognitive training. Thearpists were familiarized with manuals for cognitive training before study inception, and were instructed to adhere to the manual but were allowed to distribute time flexibly among the programs in the same cognitive domain.~In all sessions of conventional intervention group, the behavioral therapists showed several questions or instructions on the screen and then the participants answered to the questions with verbal or written words using paper and pencil.
Study NCT00128206 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: Isoniazid 900 mg twice weekly
Study NCT00128206 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: Rifampin 600mg once per day
Study NCT03954171 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Patients treated with platinum based-chemotherapy
Description: Blood samples, tumor biopsy specimens and ascites samples will be collected at different time points (if feasible, according to the samples taken in the standard practice):~* before treatment initiation (blood sample),~* during hospitalisation for surgery (blood sample),~* during follow-up consultations (blood sample).~If tumor biopsy and/or ascites sampling are performed during the standard care, a sample will be collected for the study.
Study NCT00677144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OS (oxalipaltin+S-1)
Description: Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO \[BSA \<1.25 40mg bid (total 80mg/day); BSA ≥1.25 - \<1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)\], divided by two on D1-14 every 21 days
Study NCT00677144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX (oxalipaltin+capecitabine)
Description: Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
Study NCT02679066 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sugar-tong splint
Description: Plaster immobilization including the elbow
Study NCT02679066 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Short forearm cast
Description: Fiberglass immobilization with elbow free
Study NCT01364610 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bravo
Description: Bravo pH Monitoring System sited manometrically.